A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of Helicobacter pylori: A Non-Inferiority Clinical Trial

References

• Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017;14:383–384. doi:10.1038/nrgastro.2017.57
   PubMed Web of Science ®Google Scholar
• Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367. doi:10.1136/gutjnl-2015-309252
   PubMed Web of Science ®Google Scholar
• Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609–16. doi:10.1016/S2214-109X(16)30143-7
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14:577–585. doi:10.1080/14787210.2016.1178065
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Furuta T, Fujiwara Y, et al. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther. 2020;51:534–543. doi:10.1111/apt.15641
   PubMed Web of Science ®Google Scholar
• Kuo YT, Liou JM, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707–715. doi:10.1016/S2468-1253(17)30219-4
   PubMed Web of Science ®Google Scholar
• Argueta EA, Alsamman MA, Moss SF, et al. Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population. Gastroenterology. 2021;160:2181–2183.e1. doi:10.1053/j.gastro.2021.02.014
   PubMed Web of Science ®Google Scholar
• Nyssen OP, Bordin D, Tepes B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70:40–54. doi:10.1136/gutjnl-2020-321372
   PubMed Web of Science ®Google Scholar
• Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12–22. doi:10.1016/j.pharmthera.2016.08.001
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10mg in healthy adult male subjects–a randomized open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719–730. doi:10.1111/apt.13325
   PubMed Web of Science ®Google Scholar
• Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048–1059. doi:10.1111/apt.13588
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz Y, Metz DC, Howden CW. Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther. 2021;53:794–809. doi:10.1111/apt.16295
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275–278. doi:10.1111/j.1523-5378.2007.00518.x
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-The Maastricht V/Florence consensus report. Gut. 2017;66:6–30. doi:10.1136/gutjnl-2016-312288
   PubMed Web of Science ®Google Scholar
• Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a Phase III, randomised, double-blind study. Gut. 2016;65(9):1439–1446. doi:10.1136/gutjnl-2015-311304
   PubMed Web of Science ®Google Scholar
• Sho S, Takuji G, Chika K, et al. Helicobacter pylori Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019–1026. doi:10.1136/gutjnl-2019-319954
   PubMed Web of Science ®Google Scholar
• Yi H, Xin X, Yao-Bin O, et al. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pylori infection in China: a prospective, randomized clinical pilot study. Helicobacter. 2022;27:e12896. doi:10.1111/hel.12896
   PubMed Web of Science ®Google Scholar
• Qian Z, Wen-Jia W, Shui-Ping Z, et al. helicobacter pylori Jinghua Weikang capsule for eradication: a systematic review and meta-analysis with trial sequential analysis. Front Pharmacol. 2022;13:959184. doi:10.3389/fphar.2022.959184
   PubMed Web of Science ®Google Scholar
• Graham DY, Liou JM. Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship. Clin Gastroenterol Hepatol. 2021;2021:1.
   Google Scholar
• Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–239. doi:10.1038/ajg.2016.563
   PubMed Web of Science ®Google Scholar
• Hong J, Shu X, Liu D, et al. Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial. J Antimicrob Chemother. 2016;71:2280–2285. doi:10.1093/jac/dkw118
   PubMed Web of Science ®Google Scholar
• Han R, Lu H, Jiang MW, et al. Multicenter study of antibiotic resistance profile of H. pylori and distribution of CYP2C19 gene polymorphism in rural population of Chongqing, China. Gastroenterol Res Pract. 2016;2016:8547686. doi:10.1155/2016/8547686
   PubMed Web of Science ®Google Scholar
• Jing W, Xiaolan X, Zishao Z, et al. Helicobacter pylori Prevalence of antibiotic resistance of isolates in Shanghai, China. Am J Transl Res. 2022;14:7831–7841.
   PubMed Web of Science ®Google Scholar
• Yanmeng W, Yiling L, Yuehua G, et al. Helicobacter pylori Antibiotic resistance characteristics and risk factors analysis of strains isolated from patients in Liaoning Province, an area in North China. Peer J. 2023;11:e15268. doi:10.7717/peerj.15268
   PubMed Web of Science ®Google Scholar
• Yi H, Xin X, Xiao-Shun L, et al. Helicobacter pylori Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating infection: a prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022;13:1049908.
   PubMed Web of Science ®Google Scholar
• Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11:27–37. doi:10.5009/gnl15502
   PubMed Web of Science ®Google Scholar
• Chey William D, Francis M, Loren L, et al. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163:608–619. doi:10.1053/j.gastro.2022.05.055
   PubMed Web of Science ®Google Scholar
• Ligang L, Fang L, Hekai S, et al. The efficacy and safety of vonoprazan and amoxicillin dual therapy for infection: a systematic review and network meta-analysis. Antibiotics. 2023;12:undefined.
   Google Scholar
• Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. J Gastroenterol. 2020;55:969–976. doi:10.1007/s00535-020-01709-4
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Wang M, Xu YL, Zhu Y, Lu NH, Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:1666–1672. doi:10.1111/jgh.15917
   PubMed Web of Science ®Google Scholar
• Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17(3):479–501. doi:10.1016/S0891-5520(03)00065-5
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 2000;38(3):243–270. doi:10.2165/00003088-200038030-00004
   PubMed Web of Science ®Google Scholar
• Furuta T, Sugimoto M, Yamade M, et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol. 2014;54(3):258–266. doi:10.1002/jcph.195
   PubMed Web of Science ®Google Scholar
• Gao W, Teng G, Wang C, Xu Y, Li Y, Cheng H. Eradication rate and safety of a “simplified rescue therapy”: 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: a real-world, retrospective clinical study in China. Helicobacter. 2022;27:e12918. doi:10.1111/hel.12918
   PubMed Web of Science ®Google Scholar
• Guigen T, Fangxun L. Proceedings of the 15th national clinical forum on the diagnosis and treatment of Helicobacter Pylori and digestive diseases and the fourth national summit forum on the integration of conventional Chinese and Western medicine and gastrointestinal microecology. Chin Med J. 2021;1(2):165–166.
   Google Scholar
• Zongming S, Hui Y, Jing Y, et al. Jinghua Weikang capsule protects against Helicobacter pylori-induced inflammatory responses via the nuclear factor-kappa B signaling pathway. J Tradit Chin Med. 2018;38:366–372. doi:10.1016/j.jtcm.2018.03.001
   PubMed Web of Science ®Google Scholar